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Abstract
Background: Diabetic nephropathy is the leading cause of end stage kidney disease worldwide. The pathogenesis
of this disease remains elusive and multiple factors have been implicated. These include the effects of hyperglycaemia,
haemodynamic and metabolic factors, and an inflammatory process that stimulates cellular signalling pathways leading
to disease progression and severe fibrosis. Fibronectin (Fn) is an important protein of the extracellular matrix that is
essential in fibrosis and its presence in increased amounts has been identified in the kidney in diabetic nephropathy.
Methods: Proximal tubuloepithelial (HK-2) cells were stimulated with high glucose (30 mM D-glucose) or glycated
albumin (500 μg/mmol) + 4 mM D-glucose or their controls, Mannitol (26 mM + 4 mM D-glucose) and 4 mM
D-glucose, respectively. Following 48 h of stimulation the supernatant was collected and MTT [3-(4,5-dimethylthiazole-
2,5-diphenyltetrazolium bromide] assay performed to assess cell viability. HK-2 cells were also stimulated in the above
environments with recombinant CCL18 (rCCL18) or MCP-1 (rMCP-1) for 48 h with quantification of Fn levels using
ELISA.
Results: Co-stimulation of HK-2 cells with high concentrations of glucose and rCCL18 significantly increased Fn
(p < 0.001), in comparison to high concentrations of glucose alone. HK-2 cells stimulated with glycated albumin
consistently produced Fn and this did not alter following co-stimulation with rCCL18 or rMCP-1.
Conclusion: This study demonstrates how stimulation with a specific chemokine CCL18 in high glucose
upregulates the production of Fn from proximal tubuloepithelial cells. This may be relevant to the development
of renal fibrosis in diabetic nephropathy
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Background
Diabetic nephropathy (DN) is an important complica-
tion of diabetes mellitus that despite current treatment
often results in the development of chronic kidney
disease and end stage kidney disease. The time course
for progression is variable and has traditionally been
associated with increasing proteinuria [1]; however, this
marker may now be less useful as ACEi/ARB may cause
reduction in proteinuria but not necessarily a halt in dis-
ease progression [2]. Glomerular and tubulointerstitial
fibrosis are seen in renal biopsies of those with DN and
may be a better marker of decline in renal function [3].
Understanding the mechanisms of fibrosis is therefore
important. Fibronectin (Fn) is a protein found in the
extracellular matrix and has a number of binding sites
that may bind surfaces containing collagen and heparin.
The production of Fn has been described in experimental
DN as one of the extracellular matrices that contribute to
the development of glomerulosclerosis [4]. Fn has also
been reported to be increased in the glomeruli of patient
and animal models of DN [5] and is an important marker
of fibrosis. The effect of the diabetic milieu on Fn produc-
tion by intrinsic renal cells is not fully understood.
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Fibronectin production is upregulated in immortalised
mouse podocytes stimulated with high glucose in-vitro,
supporting the profibrotic effects of the diabetic environ-
ment [6–8]. There are reports of decreased Fn produc-
tion when podocytes are stimulated with transforming
growth factor-β (TGF-β) [9]; however, the effect of this
in a diabetic environment is unclear. Podocytes treated
with insulin appear to be protected from apoptosis via
anti-angiotensin 2 mechanisms [10]. The protective
effect of insulin on podocytes has been reported to be
limited following stimulation with albumin that results
in an increase in Fn production and apoptosis [10]. A
recent study looking into the effects of toll-like receptor-
4 in a mouse model of DN has reported an upregulation
of TGF-β and Fn genes when mouse tubuloepithelial
cells were cultured in high glucose [11].
Fn levels have been reported to increase in human
proximal tubuloepithelial cells exposed to high glucose
compared with normal glucose in-vitro [12]. This finding
has been reversed using the compound Fasudil, a Rho-
associated coiled-coil forming protein serine/threonine
kinase(ROCK) inhibiting renal fibrosis. However, the ef-
fect of cytokines on Fn production in human proximal
tubuloepithelial cells in diabetic conditions is unclear.
Increasingly, studies suggest that proteinuria and loss of
renal function correlate closely with the severity of
underlying tubulointerstitial lesions [13]. Other studies
report that tubulointerstitial cells play a role in
epithelial-myofibroblast transdifferentiation (EMT) in
DN [12]. In addition, Tervaert’s histopathological classi-
fication for DN reflects an appreciation of the role of the
tubulointerstitium in DN [3]. We investigated the ability
of HK-2 cells to produce Fn and whether this is affected
by stimulation with high glucose or glycated albumin, as
found in the diabetic milieu. We then examined the ef-
fect of costimulation with recombinant chemokines
(CCL18, MCP-1) that have previously been detected in
the urine of patients with DN.
There are numerous studies reporting the importance
of inflammation in the progression and development of
DN [14]. The diabetic milieu has been reported to
induce the production of inflammatory molecules that
stimulate signalling cascades facilitating migration of
inflammatory cells [14–16]. Macrophage infiltration has
been reported in the renal biopsies of patients with dia-
betic nephropathy (DN) [3, 17]. Cytokines can orches-
trate the migration of inflammatory cells into renal
tissues [14] with some pro-inflammatory cytokines such
as tumour necrosis factor-α, interleukin-1 (IL-1), IL-6,
IL-18 contributing to renal tubular damage and pro-
gression of DN [18–20].
A number of studies have reported an association
between urinary chemokines/cytokines and the pro-
gression of DN, in particular CCN2/MCP-1 (monocyte
chemoattractant protein-1) [21]. Urinary CTGF has
been reported to correlate with the progression of DN
[22]. Our group has previously reported C-C chemo-
kine ligand 18 (CCL18/PARC) urinary levels to be
raised in proteinuric diabetic patients compared to a
non-diabetic proteinuric renal disease cohort [23].
Urinary cytokines may arise from intrinsic renal cells
or infiltrating inflammatory cells.
This study examines the effect of the diabetic milieu on
Fn production by HK-2 cells in-vitro. In addition, the ef-
fects of stimulation with recombinant CCL18 (rCCL18) or
recombinant MCP-1 (rMCP-1) on Fn production from
HK-2 cells are reported.
Methods
Materials
30 mM D-glucose was used as high glucose concentra-
tion for the following experiments, with Mannitol used
as the osmotic control (26 mM +4 mM of D-glucose).
Glycated albumin (A8301, Sigma, Gillingham, UK) was
used at a concentration of 500 μg/ml +4 mM D-glucose,
with physiological 4 mM D-glucose used as its control.
The Fn ELISA was carried out using rabbit anti-human
Fn polyclonal Ab for capture (F3648, Sigma, Gillingham,
UK) and biotinylated murine anti-human Fn monoclonal
Ab (F7387, Sigma, Gillingham, UK) for detection. Fn
derived from human plasma was used as the antigen for
the standard curve (range 1.95-2000 pg/ml) (F0895,
Sigma, Gillingham, UK).
Recombinant human CCL18 (394-PA, R&D systems,
Abingdon, UK) and MCP-1 (279-MC, R&D systems,
Abingdon, UK) were reconstituted according to the
manufacturer’s instructions. Following dose response ex-
periments, HK-2 cells were stimulated with recombinant
CCL18 or rMCP-1 at a concentration of 20 ng/ml for
48 h. Fn levels were subsequently measured from the
cell supernatant using ELISA.
Cell culture
HK-2 cells are an immortalised proximal tubuloepithelial
cell line from normal adult human kidney that was a gift
from Professor Roger Mason, Imperial College London,
London, UK. Cells were grown at 37 °C in T75 tissue
culture flasks until 70 % confluent and then 5x106 cells
were seeded into 6 well plates and maintained in kera-
tinocyte media supplemented with bovine pituitary
extract and epidermal growth factor (Life Technologies,
GIBCO), 5% FCS, penicillin and streptomycin. Once
the cells reached 70 % confluence in the 6 well plates,
they were maintained for a further 24 h before their
media was changed to RPMI 1640 supplemented with
1000U/ml penicillin, 100 g/ml streptomycin and 2 mM
glutamine without serum.
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Proximal tubuloepithelial cells are intrinsic renal cells
that may be associated with release of cytokines in the
urine. Pilot studies were performed using HK-2 cells
stimulated with cytokines (Montero, unpublished data)
previously identified in the urine of patients with DN
[21, 23]. These studies suggested an interaction between
HK-2 cells in the diabetic environment stimulated with
rCCL18 or rMCP-1, hence informing the design of this
study.
The glucose condition of choice (see above) was
placed in each well alone (n = 6) or co-stimulated with
rCCL18 (n = 6) or rMCP-1 (n = 6) for 48 h. Each condi-
tion was replicated in 6 wells for each experiment. Each
experiment was repeated three times to ensure reprodu-
cible results. The plates were incubated and the superna-
tants were collected at 48 h.
Analysis of samples
Supernatants were collected from the 6 well plates and cen-
trifuged to remove cell debris. The supernatants were
stored at -80 °C for later analysis. The [3-(4,5-dimethylthia-
zole-2,5-diphenyltetrazolium bromide], (MTT) assay
(Sigma, UK) was performed on the 3 wells for each cul-
tured condition to assess cell viability and read on the
ELISA plate reader at 550 nm. Direct cell count was per-
formed using Trypan blue exclusion assay (Sigma, UK).
Enzyme-linked Immunoabsorbent Assay (ELISA)
The fibronectin in the cell culture supernatant samples
was quantified by ELISA. Briefly Fn capture Ab was used
to coat a 96 well Nunc plate overnight at 4 °C. The plate
was washed three times and incubated in blocking solu-
tion for 1 h. The plate was washed thrice and the sam-
ples and standard applied, leaving the plate to incubate
overnight at 4 °C. The plate was washed three times and
incubated for 1 h with the detection Ab. The plate was
washed and the Streptavidin, Substrate and Stop solution
steps were as per standard ELISAs. The ELISA plate
reader was used at 492 nm wavelength. Intra and inter-
assay variability was 5.4 % and 8.7 %, respectively.
Statistics
Graph Pad PRISM software (version 4) was used to per-
form data analysis. Fibronectin concentration was ana-
lysed using Kruskal-Wallis with Dunn’s post analysis
for multiple comparisons. MTT assay and direct cell
count with Trypan blue exclusion assay results were
presented as mean ± SD and assessed using Analysis of
variance with Bonferroni’s correction for multiple com-
parisons. P value < 0.05 compared with the control
were considered as statistically significant.
Results
Diabetic milieu
Effect of high concentration of glucose on fibronectin
production
Fn was detected in the supernatant of HK-2 cells following
48 h stimulation with high glucose with similar levels seen
in the osmotic control mannitol (median 6948 μg/ml
(range 3414–11250) and median 4883 μg/ml (range
2971–5405), respectively, non-significant) (Fig. 1).
Effect of glycated albumin on fibronectin production
Fn was detected in the supernatant of HK-2 cells follow-
ing 48 h stimulation with physiological glucose (4 mM
D-glucose) at a median concentration of 6813 μg/ml
(range 6112–8210) and when stimulated with glycated
albumin in the presence of 4 mM D-glucose at median
Fn levels of 7976 μg/ml (range 5998–10410). Differences
were not significant (Fig. 1).
Recombinant cytokines
Effect of co-stimulation with rCCL18 on fibronectin
production
There was a significant rise in the levels of Fn in the
supernatant of HK-2 cells following stimulation with
rCCL18 in the presence of high concentrations of glu-
cose compared to high concentrations of glucose only
(p < 0.001) (Fig. 1). The Fn levels were not significantly
Fig. 1 The production of fibronectin (Fn) by HK-2 cells stimulated
with recombinant CCL18 for 48 h in a diabetic milieu. A significantly
higher concentration of Fn was produced by HK-2 cells stimulated with
recombinant CCL18 in high concentration of glucose in comparison
to CCL18 only or high glucose concentration only. P < 0.001. Key:
N0 = physiological glucose, A0 = glycated albumin, M0 = mannitol,
H0 = high glucose, N20 = physiological glucose + 20 ng/ml CCL18,
A20 = glycated albumin + 20 ng/ml CCL18, M20 =mannitol + 20 ng/ml
CCL18, H20 = high glucose + 20 ng/ml CCL18
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raised in glycated albumin conditions with rCCL18, in
comparison to glycated albumin only at 48 h.
Effect of co-stimulation with rMCP-1 on fibronectin
production
There were no significant differences in the Fn levels in
the supernatant of HK-2 cells cultured with glycated albu-
min or high glucose when stimulated with rMCP-1 for
48 h, compared with those without additional rMCP-1
(Fig. 2).
Cell viability assays
MTT assay showed an overall decrease in cell viability
of HK-2 cells cultured in glycated albumin that did not
alter following co-stimulation with cytokines. There
were an increased number of surviving cells in high
glucose conditions, but the difference did not reach
statistical significance (Tables 1 and 2). We further in-
vestigated the number of viable cells in cells stimulated
with high glucose concentration with or without re-
combinant stimulation with CCL18 using trypan blue
exclusion assay. We found that the number of viable
cells was not signficantly different between stimulation
with high concentration of glucose only vs manitol
osmolarity control and recombinant CCL18 vs high
concentration of glucose and recombinant CCL18
(Table 2). The number of viable cells cultured with
mannitol and normal glucose concentration was lower
than in the other conditions.
In conclusion, there is increased production of fibro-
nectin in HK2 cells stimulated with combination of re-
combinant CCL18 and high glucose concentration, in
comparison to high concentration of glucose only or re-
combinant CCL18 and mannitol control with normal
glucose concentration. The number of viable HK2 cells
were not significantly different when assessed by both
MTT and trypan blue exclusion assays.
Discussion
This study demonstrates that HK-2 cells in high glucose
co-stimulated with rCCL18 in-vitro increase the produc-
tion of Fn compared to a high concentration of glucose
only. This result cannot be explained by differences in
cell viability, with no significant difference seen by direct
cell count using trypan blue exclusion assay or MTT
assay. Increased Fn production was not seen following
co-stimulation with rMCP-1 or with glycated albumin.
The MTT assay showed an overall decrease in cell viabil-
ity of HK-2 cells in glycated albumin that did not alter
with co-stimulation with rCCL18 or rMCP-1. Previous
studies have reported an increase in Fn production be-
tween physiological and high glucose that was not seen
in our present study [12]. Gu and colleagues measured
fibronectin following stimulation with a much higher
concentration (60 mmol/L) of D-glucose on HK-2 cells
for a long duration of 72 h, and thus the difference in
time course may explain the discrepancy between our
findings.
It is established in DN that excess glucose binds to
free amino acids on tissue proteins or those in the circu-
lation. The non-enzymatic glycosylation that occurs, re-
sults in the formation of Advanced Glycated End
Products (AGEPs). Initially, these bonds are reversible
and attach to the matrix components of the glomerulus
or the GBM; later, these bonds become irreversible. The
AGEPs can accumulate throughout the body’s tissues as
they are unable to be excreted due to the glomerular
damage. Increasing amounts of AGEPs in tissues may
result in microvascular complications [24]. Nitric oxide
(NO) concentrations are reduced in a dose-dependent
manner with the formation of AGEPs, exacerbating
hypertension [25]. The advanced products then interfere
with signal transduction. This may occur by changing
soluble signals such as cytokines, hormones and free
radicals. AGEPs are also known to be profibrotic in
humans, interacting with the renin angiotensin system,
cell signalling and RAGE, all disrupting the cellular
matrix [26].
We therefore used glycated albumin as an advanced
glycated protein to stimulate HK-2 cells to determine
whether this would induce a different response in Fn
production and whether this could be affected by stimu-
lation with recombinant chemokines. The CCL18 effect
Fig. 2 The production of fibronectin by HK-2 cells stimulated with
recombinant MCP-1 for 48 h in a diabetic milieu. There were no
any significant differences in Fn production in HK-2 cells stimulated
under different conditions. Key: N0 = physiological glucose, A0 = glycated
albumin, M0 = mannitol, H0 = high glucose, N20 = physiological
glucose + 20 ng/ml MCP-1, A20 = glycated albumin + 20 ng/ml
MCP-1, M20 =mannitol + 20 ng/ml MCP-1, H20 = high glucose +
20 ng/ml MCP-1
Montero et al. BMC Nephrology  (2016) 17:139 Page 4 of 7
on Fn production observed in high glucose was not seen
with glycated albumin. These results suggested that the
synergistic effects of CCL18 and high glucose concentra-
tion on Fn production are not dependent on stimulation
of RAGE, or that the effect was limited by reduced via-
bility of glycated albumin stimulation. The toxicity of
albumin on proximal tubuloepithelial cells has previ-
ously been reported [27]. It appears that CCL18 or
MCP-1, are unable to induce mechanisms to prevent the
toxic effect of glycated albumin on these cells [28].
CCL18 is not produced by HK-2 cells (Montero un-
published data); however, these cells respond to CCL18
in a profibrotic manner. CCL18 has previously been de-
scribed to be released from alternatively activated mac-
rophages that contribute to idiopathic lung fibrosis [29,
30]. In addition, serum CCL18 has been described to be
raised in patients with lung fibrosis [31], scleroderma
[32], inflammatory diseases such as rheumatoid arthritis
[33], acute lymphoblastic leukaemia [34] and gastric ma-
lignancies [35]. Inflammatory cells have been described
to infiltrate the renal parenchyma in diabetic nephropa-
thy in humans and also in rodent models [27, 36]. The
ability of HK-2 cells to respond to CCL18 to alter the
production of Fn in a high glucose environment, but not
in physiological glucose, illustrates that the effect of a
cytokine also depends on the metabolic environment.
Fn is an important matrix component that is detected
in the glomeruli and tubulointerstitium of the kidneys
during development and later in adulthood [37–39].
Proximal tubuloepithelial cells have previously been
shown to produce Fn through activation of ERK, p38
MAPK, PKCα and PKCβII signalling pathways [40]. Fn
production may subsequently be increased further
through its downstream activation of TGF-β1, which
leads to further fibrosis. Cell associated Fn has been
reported to regulate cell-matrix interactions thereby sta-
bilising the ECM [41, 42]. In contrast, soluble Fn has
more of an immunoregulatory role in murine tubuloe-
pithelial cells, causing an increase in MCP-1 and
macrophage inflammatory protein-2 via ERK and NF-
kB pathways [43]. The ability of HK-2 cells to produce
variable amounts of Fn determined by their local envir-
onment illustrates the complexity of signalling path-
ways that may be induced or inhibited in association
with different factors [44]. Further studies are needed
to determine the underlying cell signalling pathways
that result in an increase in Fn seen in HK-2 cells co-
stimulated with CCL18 in high concentrations of
glucose.
Urinary MCP-1 has been reported to be increased in
patients with microalbuminuria and macroalbuminuria,
with the latter predictive of progression of DN [21, 45].
This study showed no change in the production of Fn in
HK-2 cells in a diabetic milieu with rMCP-1 co-
Table 2 Number of viable HK-2 cells (assessed by trypan blue
exclusion assay), in different experimental conditions with or
without co-stimulation recombinant CCL18 for 48 h
Condition with 0 ng/ml or
20 ng/ml of recombinant
cytokine stimulation
Number of live cells for HK-2 cells
stimulated without or with rCCL18
(x1000 cells per well, Mean ± SD)
M0 288 ± 17 **
H0 467 ± 22
M20 420 ± 22
H20 437 ± 43
Abbreviations: M0 = mannitol control + normal glucose, H0 = high glucose,
M20 = mannitol + normal glucose + 20 ng/ml CCL18, H20 = high glucose +
20 ng/ml CCL18. The number of viable cells were assessed by direct cell
count with trypan blue exclusion assay. The results are presented as mean ±
SD. The data were tested by Analysis of Variance with Bonferroni’s correction
for multiple comparisons. The number of viable cells were lower in cells
culture in the M0 group (**p < 0.01), in comparison to the cells culture in
other conditions. There was no significant differences in cell counts between
H0, M20 and H20 groups
Table 1 MTT assay of HK-2 cells in different experimental conditions and with or without co-stimulation with recombinant cytokines
rCCL18 or rMCP-1 for 48 h
Condition with 0 ng/ml or 20 ng/ml
of recombinant cytokine stimulation
MTT assay for HK-2 cells stimulated
without or with rCCL18
Mean ± SD
MTT assay for HK-2 cells stimulated
without or with rMCP-1
Mean ± SD
N0 0.664 ± 0.024 0.404 ± 0.072
A0 0.331 ± 0.040 ** 0.107 ± 0.029 *
M0 0.692 ± 0.073 0.390 ± 0.005
H0 0.843 ± 0.131 0.603 ± 0.033
N20 0.633 ± 0.085 0.517 ± 0.059
A20 0.353 ± 0.042 ** 0.263 ± 0.199
M20 0.590 ± 0.113 0.183 ± 0.008
H20 0.758 ± 0.057 0.365 ± 0.178
Abbreviations: N physiological glucose, A glycated albumin, M mannitol, H high glucose
Legend to Table 2: The results from two independent experiments are shown. MTT assay were carried out for 3 wells with each of the cell culture conditions. The
results are presented as mean ± SD. The data were tested by Analysis of Variance with Bonferroni’s correction for multiple comparisons. **p < 0.01, * p < 0.05, in
comparison to the cells culture in normal glucose concentration
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stimulation. This would suggest that local production of
MCP-1 may contribute to inflammatory cell recruitment
but not directly to changes in the extracellular matrix,
unlike CCL18.
This study has certain limitations. We examined pro-
tein levels of Fn but not mRNA levels in HK-2 cells,
and thus could not distinguish between the different
spliced forms of Fn (EDA+/-). Future experiments can
be conducted to determine the predominant form of Fn
produced. The findings from in-vitro studies may not
be representative of in-vivo studies; however, there is
no rodent equivalent of CCL18.
Despite the limitations of in-vitro cell culture, this
work allows some insight into the pathogenesis of DN.
The cytokines examined have been reported to be raised
in patients with DN and albuminuria. The synergistic
effect of CCL18 with high glucose to increase the pro-
duction of Fn in HK-2 cells illustrates the importance
and complexity of the roles of inflammatory, metabolic
and fibrotic pathways. Understanding how these may
interlink will help in the prevention of the progression
of DN.
Conclusion
This study demonstrates that stimulation with chemo-
kine CCL18 in high glucose upregulates the production
of Fn from proximal tubuloepithelial cells. This may ex-
plain fibrotic changes in diabetic nephropathy. Further
studies are required to elucidate the cell signalling
events that induce these effects and correlate them with
clinical findings.
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